- Persistent Racial Disparities: Black people continue to be consistently underrepresented in clinical trials for inflammatory arthritis, while White people are consistently overrepresented. This disparity extends to conditions like rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, and juvenile idiopathic arthritis.
- Disease Burdens and Overlooked Research: Racial and ethnic minority groups often bear a higher disease burden, experiencing more severe symptoms and worse health scores, yet they frequently get overlooked in research efforts.
- Guidelines for Inclusion: Academic and regulatory authorities have set guidelines to ensure diversity in clinical trials, such as the U.S. National Institutes of Health (NIH) requiring NIH-funded research to include minority groups and the FDA's efforts to improve data analysis by addressing demographic subgroups.
- Study Methodology: The study systematically reviewed new inflammatory arthritis drugs approved by the FDA from July 2012 to June 2022 and examined the clinical trials associated with these drugs. The investigators identified 34 new drug approvals across various drug subtypes, involving both biologics and small molecule inhibitors.
- Disparities in Enrollment: The investigators found that White participants were consistently overrepresented in most trials, while Black participants were consistently underrepresented. Additionally, there were relative heterogeneities in enrollments for Asian and Hispanic participants. Over time, White participants increased their involvement in certain trials, while the involvement of Black, Asian, and Hispanic participants fluctuated in various trials.